Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drug could help mental health patients shed pounds

NCT ID NCT06754163

Disease control Sponsor: St Andrew's Healthcare Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide (Wegovy), a weekly injection for weight loss, can help people in secure mental health care who have gained weight from antipsychotic drugs like clozapine or olanzapine. About 20 adults with a BMI of 35 or higher will receive the drug along with diet, exercise, and psychological support for up to 24 months. The goal is to reduce obesity and related health problems, not to cure the underlying psychiatric condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI of 35.0 kg/m2 or above or BMI of 32.5 kg/m2 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family * Aged 18 or above * Able to give informed consent, as assessed by their RC. In the context of participation in this trial 'informed' consent includes having an understanding of the dietary and exercises changes needed for the treatment to be effective * Currently prescribed olanzapine or clozapine * Currently in an inpatient service at St Andrew's Healthcare * Sufficient level of English to read and understand the information sheet (may require verbal explanation from support from staff) Exclusion Criteria: * Aged 17 or under * Meet any of the contraindications, including hypersensitivity to the active substance or to any of the excipients * Pregnant or likely to become pregnant * Diagnoses of dementia or Huntington's disease * On a PICU/acute ward * Discharge anticipated to be in 6 months' time or less

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder psychiatric disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity and obesity-related medical conditions Psychiatric disorders

Contacts and locations

Locations

  • St Andrew's Healthcare

    Northampton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.